Active, not recruitingNot applicableNCT06829589
Retrieval of Economic Incentives and Information on Quality-of-care Indicators in Primary Care
Studying Idiopathic pulmonary arterial hypertension
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina
- Intervention
- Removal of economic incentives linked to 7 quality-of-care indicators(other)
- Enrollment
- 1614 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2026
Study locations (30)
- ABS Artés, Artés, Barcelona, Spain
- ABS Berga, Berga, Barcelona, Spain
- ABS Calaf, Calaf, Barcelona, Spain
- ABS Canet de Mar, Canet de Mar, Barcelona, Spain
- ABS Capellades, Capellades, Barcelona, Spain
- ABS Cardona, Cardona, Barcelona, Spain
- ABS Moià, Castellterçol, Barcelona, Spain
- ABS Cubelles-Cunit, Cubelles, Barcelona, Spain
- EAP Penedès Rural Est, Els Monjos, Barcelona, Spain
- EAP Penedès Rural Oest, Els Monjos, Barcelona, Spain
- ABS Baix Berguedà, Gironella, Barcelona, Spain
- ABS Alt Berguedà, Guardiola de Berguedà, Barcelona, Spain
- ABS Igualada urbana, Igualada, Barcelona, Spain
- ABS Anoia Rural, La Pobla de Claramunt, Barcelona, Spain
- ABS Manlleu, Manlleu, Barcelona, Spain
- +15 more locations on ClinicalTrials.gov
Collaborators
Catalan Institute of Health
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06829589 on ClinicalTrials.govOther trials for Idiopathic pulmonary arterial hypertension
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT06605794FreeFlow Percutaneous Atrial Septal Shunt for IPAHShanghai Zhongshan Hospital
- ACTIVE NOT RECRUITINGNCT05723185Primary Care-Hospital Embedding: a Prospective, Multicentric, Observational StudyRovere Querini Patrizia
- RECRUITINGNANCT05584722Risk and Resilience in Pulmonary Arterial Hypertension and Genetically Susceptible IndividualsVanderbilt University Medical Center
- ACTIVE NOT RECRUITINGPHASE2NCT05679570Satralizumab in the Treatment of Pulmonary Arterial Hypertension (SATISFY-JP Trial)International University of Health and Welfare
- RECRUITINGNCT04756076Study Roles of Heavy Metals and Essential Metal Dyshomeostasis in Pulmonary Arterial Hypertension PatientsJiapeng Huang
See all trials for Idiopathic pulmonary arterial hypertension →